News
REGMF
11.00
NaN%
--
Citic Securities Remains a Buy on RemeGen Co. Ltd. Class H (9995)
TipRanks · 2d ago
Vor Bio rises after partner RemeGen succeeds in Sjögren’s disease study
Seeking Alpha · 10/14 13:04
Weekly Report: what happened at REGMF last week (0908-0912)?
Weekly Report · 09/15 11:10
Weekly Report: what happened at REGMF last week (0901-0905)?
Weekly Report · 09/08 11:12
Weekly Report: what happened at REGMF last week (0825-0829)?
Weekly Report · 09/01 11:07
Weekly Report: what happened at REGMF last week (0818-0822)?
Weekly Report · 08/25 11:18
Weekly Report: what happened at REGMF last week (0811-0815)?
Weekly Report · 08/18 11:10
Vor Bio, RemeGen succeed in trial for telitacicept in China
Seeking Alpha · 08/13 13:49
Vor Bio: RemeGen Achieves Primary Endpoint In Phase 3 Study In China Evaluating Telitacicept
NASDAQ · 08/13 12:46
Weekly Report: what happened at REGMF last week (0804-0808)?
Weekly Report · 08/11 11:17
Weekly Report: what happened at REGMF last week (0728-0801)?
Weekly Report · 08/04 11:20
Weekly Report: what happened at REGMF last week (0721-0725)?
Weekly Report · 07/28 11:20
Weekly Report: what happened at REGMF last week (0714-0718)?
Weekly Report · 07/21 11:10
Weekly Report: what happened at REGMF last week (0707-0711)?
Weekly Report · 07/14 11:20
Weekly Report: what happened at REGMF last week (0630-0704)?
Weekly Report · 07/07 11:11
Weekly Report: what happened at REGMF last week (0623-0627)?
Weekly Report · 06/30 11:18
Vor Bio surges after private placement, licensing deal
Seeking Alpha · 06/26 15:54
Why Vor Bio Is Rising In Pre-market?
NASDAQ · 06/26 11:09
Weekly Report: what happened at REGMF last week (0616-0620)?
Weekly Report · 06/23 11:10
Weekly Report: what happened at REGMF last week (0609-0613)?
Weekly Report · 06/16 11:17
More
Webull provides a variety of real-time REGMF stock news. You can receive the latest news about Remegen through multiple platforms. This information may help you make smarter investment decisions.
About REGMF
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.